Hjem › Akut myelogen leukemi › New York › Rochester
Kliniske studier for Akut myelogen leukemi i Rochester, NY
16 studier for Akut myelogen leukemi søker deltakere på steder i og rundt Rochester (innen ca. 30 miles). Åpne et studie for å se hvem som kan delta og hvordan du kontakter studieteamet.
Offisiell studietekst (engelsk)
Rekrutterer til et studie her? Få det fremtredende øverst på siden – $99 i 30 dager →
MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)
RekruttererFase 2
- Rochester General Hospital, Rochester
- University of Rochester, Rochester
Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial)
RekruttererFase 2
- University of Rochester, Rochester
A Study of Bleximenib, Venetoclax and Azacitidine For Treatment of Participants With Newly Diagnosed Acute Myeloid Leukemia (AML)
RekruttererFase 3
- University of Rochester Medical Center, Rochester
Comparing New Treatments for People With Newly Diagnosed Acute Myeloid Leukemia That Has an IDH2 Gene Change (A MyeloMATCH Treatment Trial)
RekruttererFase 2
- University of Rochester, Rochester
Testing New Therapies for Patients With Acute Myeloid Leukemia Who Are Newly Diagnosed and Have Not Yet Started Treatment (A MyeloMATCH Treatment Trial)
RekruttererFase 2
- University of Rochester, Rochester
Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial)
RekruttererFase 2
- University of Rochester, Rochester
A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations
RekruttererFase 3
- University of Rochester, Rochester
A Telehealth Advance Care Planning Intervention
Rekrutterer
- University of Rochester, Rochester
Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia
RekruttererFase 1
- Wilmot Cancer Institute, University of Rochester, Rochester
Mocravimod as Adjunctive and Maintenance Treatment in AML Patients Undergoing Allo-HCT
RekruttererFase 3
- University of Rochester Medical Center (URMC), Rochester
A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)
RekruttererObservasjonsstudie
- Strong Memorial Hospital/University of Rochester, Rochester
A Decisional Intervention for Older Adults With Acute Myeloid Leukemia and Their Caregivers
Rekrutterer
- University of Rochester Medical Center, Rochester
Hyperbaric Oxygen Therapy and Allogeneic Peripheral Blood Stem Cell (PBSC) Transplant
RekruttererTidlig fase 1
- Wilmot Cancer Institute, University of Rochester, Rochester
A Study of CTX-712 in Relapsed/Refractory Acute Myeloid Leukemia and Higher Risk Myelodysplastic Syndromes
RekruttererFase 1/2
- The University of Rochester, Rochester
Monitoring Minimal Residual Disease of Patients With Acute Myelogenous Leukemia or High Grade Myelodysplastic Syndrome
RekruttererObservasjonsstudie
- University of Rochester Medical Center, Rochester
Specialty Compared to Oncology Delivered Palliative Care for Patients With Acute Myeloid Leukemia
RekruttererFrivillige helsepersonell ønskes velkommen
- University of Rochester, Rochester
Akut myelogen leukemi-studier i andre byer
- Houston, TX85 studier
- New York City, NY51 studier
- Boston, MA44 studier
- Seattle, WA41 studier
- Baldwin Park, CA40 studier
- Columbus, OH35 studier
- Philadelphia, PA34 studier
- Durham, NC33 studier
- Atlanta, GA31 studier
- Tampa, FL29 studier
- Chicago, IL26 studier
- Portland, OR25 studier
Andre studier i Rochester
- Lungekreft15 studier
- Brystkreft15 studier
- Kreft (alle typer)14 studier
- Fedme14 studier
- Overvekt13 studier
- Ikke-småcellet lungekreft13 studier
- Prostatakreft10 studier
- Metastatisk kreft8 studier
- Multipelt myelom8 studier
- Blærekreft7 studier
- Myotonisk dystrofi7 studier
- Pankreaskreft7 studier
Fra ClinicalTrials.gov, data hentet 6. okt. 2026. Hver studie setter sine egne kvalifikasjonskrav; studieteamet avgjør hvem som kan delta.